DK2448933T3 - Trans-4-[[(5S)-5-[[[3,5-bis(trifluormethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexancarboxylsyre - Google Patents

Trans-4-[[(5S)-5-[[[3,5-bis(trifluormethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexancarboxylsyre

Info

Publication number
DK2448933T3
DK2448933T3 DK10728558.7T DK10728558T DK2448933T3 DK 2448933 T3 DK2448933 T3 DK 2448933T3 DK 10728558 T DK10728558 T DK 10728558T DK 2448933 T3 DK2448933 T3 DK 2448933T3
Authority
DK
Denmark
Prior art keywords
methyl
benzazepin
tetrazol
tetrahydro
trifluoromethyl
Prior art date
Application number
DK10728558.7T
Other languages
Danish (da)
English (en)
Inventor
Xinchao Chen
Scott Alan Frank
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2448933(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2448933T3 publication Critical patent/DK2448933T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK10728558.7T 2009-06-30 2010-06-28 Trans-4-[[(5S)-5-[[[3,5-bis(trifluormethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexancarboxylsyre DK2448933T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (1)

Publication Number Publication Date
DK2448933T3 true DK2448933T3 (da) 2013-10-07

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10728558.7T DK2448933T3 (da) 2009-06-30 2010-06-28 Trans-4-[[(5S)-5-[[[3,5-bis(trifluormethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexancarboxylsyre

Country Status (37)

Country Link
US (2) US8299060B2 (https=)
EP (1) EP2448933B1 (https=)
JP (1) JP5689875B2 (https=)
KR (1) KR101404893B1 (https=)
CN (1) CN102639528B (https=)
AR (1) AR077208A1 (https=)
AU (1) AU2010266537B2 (https=)
BR (1) BRPI1011931A2 (https=)
CA (1) CA2764425C (https=)
CL (1) CL2011003263A1 (https=)
CO (1) CO6480934A2 (https=)
CR (1) CR20110669A (https=)
DK (1) DK2448933T3 (https=)
DO (1) DOP2011000405A (https=)
EA (1) EA020600B1 (https=)
EC (1) ECSP11011551A (https=)
ES (1) ES2435293T3 (https=)
GT (1) GT201100321A (https=)
HR (1) HRP20130950T1 (https=)
IL (1) IL216655A (https=)
JO (1) JO2867B1 (https=)
MA (1) MA33385B1 (https=)
ME (1) ME01606B (https=)
MX (1) MX2011014024A (https=)
MY (1) MY157121A (https=)
NZ (1) NZ596820A (https=)
PE (1) PE20120538A1 (https=)
PL (1) PL2448933T3 (https=)
PT (1) PT2448933E (https=)
RS (1) RS52988B (https=)
SG (1) SG177413A1 (https=)
SI (1) SI2448933T1 (https=)
TN (1) TN2011000638A1 (https=)
TW (1) TWI450896B (https=)
UA (1) UA109409C2 (https=)
WO (1) WO2011002696A1 (https=)
ZA (1) ZA201108707B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
SG10201605304VA (en) * 2011-07-08 2016-08-30 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
WO2014012401A1 (zh) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
ES2642172T3 (es) 2013-01-31 2017-11-15 Chong Kun Dang Pharmaceutical Corp. Compuestos derivados de ciclohexeno sustituidos con biarilo o biarilo heterocíclico como inhibidores de CETP
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
MX384679B (es) 2014-07-30 2025-03-14 Hoffmann La Roche Marcadores genéticos para predecir la reactividad a terapia con agente que eleva la lipoproteína de alta densidad (hdl) o que imita la lipoproteína de alta densidad (hdl).
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (https=) 1970-12-15 1974-12-23
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
MXPA03009935A (es) 2001-04-30 2004-01-29 Pfizer Prod Inc Metodos e intermedios para preparar inhibidores 4-aminoquinolina de cetp.
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
WO2004032848A2 (en) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1601655A2 (en) 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
DE602004023100D1 (de) 2003-10-08 2009-10-22 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidemie
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
CA2764425C (en) 2015-01-06
CN102639528A (zh) 2012-08-15
UA109409C2 (ru) 2015-08-25
US8329688B2 (en) 2012-12-11
MX2011014024A (es) 2012-04-20
AR077208A1 (es) 2011-08-10
SI2448933T1 (sl) 2013-11-29
MA33385B1 (fr) 2012-06-01
JP2012532106A (ja) 2012-12-13
BRPI1011931A2 (pt) 2016-04-19
TN2011000638A1 (en) 2013-05-24
EP2448933B1 (en) 2013-08-28
GT201100321A (es) 2012-11-15
TW201113275A (en) 2011-04-16
EA020600B1 (ru) 2014-12-30
MY157121A (en) 2016-05-13
US20100331309A1 (en) 2010-12-30
EP2448933A1 (en) 2012-05-09
ECSP11011551A (es) 2012-01-31
NZ596820A (en) 2013-07-26
CL2011003263A1 (es) 2012-07-27
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
TWI450896B (zh) 2014-09-01
AU2010266537A1 (en) 2012-02-02
CO6480934A2 (es) 2012-07-16
CR20110669A (es) 2012-03-16
US8299060B2 (en) 2012-10-30
WO2011002696A1 (en) 2011-01-06
IL216655A0 (en) 2012-02-29
EA201270099A1 (ru) 2012-05-30
PT2448933E (pt) 2013-10-29
SG177413A1 (en) 2012-02-28
US20120058990A1 (en) 2012-03-08
CN102639528B (zh) 2014-07-16
ZA201108707B (en) 2013-05-29
CA2764425A1 (en) 2011-01-06
ES2435293T3 (es) 2013-12-18
KR101404893B1 (ko) 2014-06-20
IL216655A (en) 2015-02-26
KR20120027426A (ko) 2012-03-21
PE20120538A1 (es) 2012-05-09
JP5689875B2 (ja) 2015-03-25
HRP20130950T1 (hr) 2013-11-22
JO2867B1 (en) 2015-03-15
AU2010266537B2 (en) 2013-04-18
PL2448933T3 (pl) 2014-01-31
DOP2011000405A (es) 2012-01-15

Similar Documents

Publication Publication Date Title
DK2448933T3 (da) Trans-4-[[(5S)-5-[[[3,5-bis(trifluormethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexancarboxylsyre
ITCO20080005A1 (it) "shaker monouso"
BRPI0815277A2 (pt) "monitores de particulado"
BRPI0811280A2 (pt) Compostos amino-heterocíclicos
SMT201400010B (it) Purificazione di 1-[2-(2,4-dimetilfenilsolfanil)fenilÜpiperazin a
IL220234B (en) Tal effector-mediated dna modification
EP2421537A4 (en) PYRAZOLYLAMINOPYRIDINE AS A FAK HEMMER
BRPI0914772A2 (pt) compostos heterocíclicos 1,2-dissubstituídos
BRPI0922904A2 (pt) "compostos"
DK2031948T3 (da) Bestemmelse af en komponents brugstid
EP2471026A4 (en) PICTURE SELECTION ON RELEVANT BASIS
EP2475028A4 (en) BATTERY MODULE
BRPI0719693A2 (pt) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2- (demetilamino)etil]-2-metóxi-alfa-1-naftalenil-beta- fenil-3-quinolinaetanol
EP2244576A4 (en) 3,5-substituted-1,3-oxazolidine-2-one derivatives
ATE533761T1 (de) Imidazolidinonderivate
CU20090141A7 (es) Compuestos 2-amino pirimidina
EP2141154A4 (en) OXAZOLIDINONE DERIVATIVITY WITH HEMMETIC EFFECT ON TYPE I 11-HYDROXYSTEROIDDEHYDROGENASE
DK2125714T3 (da) Hydrochloridsalt af 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamid
EP1937650A4 (en) HETEROCYCLIC COMPOUNDS
IL209197A0 (en) 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
EP2097474A4 (en) HEAT-RESISTANT THERMOPLASTIC VULCANATE COMPOUNDS
BRPI1014847A2 (pt) "cartucho de lâmina"
EP2252281A4 (en) BLOOD SUBSTITUTE SOLUTIONS
ATE467618T1 (de) Chinolinylmethylverbindungen
EP2367935A4 (en) Acidothermus celluloyticus xylanase